Sentence examples for mice with intraperitoneal from inspiring English sources

(b) 0.25 nmol 68Ga-IMP288 (5 MBq) and 18F-FDG (5 MBq) 1 h after i.v. injection in the BALB/c nude mice with intraperitoneal CEA-expressing LS174T tumors.

(a) 6.0 nmol 125I-TF2 (0.37 MBq) and 0.25 nmol 68Ga-IMP288 (5 MBq) 1 h after i.v. injection of 68Ga-IMP288 in BALB/c nude mice with intraperitoneal CEA-expressing LS174T tumors.

3D-volume rendering of the pretargeted immuno-PET scan (a) and the FDG-PET/CT scan (b) of the BALB/c nude mice with intraperitoneal LS174T tumors that received 6.0 nmol TF2 and 5 MBq 68Ga-IMP288 (0.25 nmol) with a 16-h interval (a) or 18F-FDG (b).

Dose-escalation studies with dFdC were performed in ICR mice with intraperitoneal application over 5 days.

An allergic rhinitis model was successfully established by sensitizing mice with intraperitoneal OVA and then challenging them with an intranasal OVA drip [ 26].

Experimentally, plasma cell tumors (peritoneal plasmacytomas) could be induced in up to 80% of genetically susceptible mice with intraperitoneal injection of silicone gels and oils [ 9, 44].

The image quality of the 155Tb-based SPECT scans was convincing and allowed not only the visualization of subcutaneous tumor xenografts, but also smallest lesions in the abdominal tract of a mouse with intraperitoneal SKOV-3ip xenografts [10].

Two SCID-mice with intraperitoneal MDA-MB-435 xenografts were treated with 6×1.85 MBq 213Bi-DTPA-[F3]2 between the days 4 and 14 after inoculation of tumor cells as described above, two others with 6×100 µl PBS.

Experimental autoimmune encephalomyelitis (EAE) was induced in C57BL/6 mice, and severity of EAE was monitored in mice treated with intraperitoneal (i.p).

Histologic and electron microscopic images of mice treated with intraperitoneal lipopolysaccharide (LPS) from Escherichia coli 0111 B4 in a dose of 0.25 mg for 4 h are presented in lower panels.

Furthermore, Buckley et al. (2008) demonstrated that when imaging in the nasal and pulmonary airways of mice, compared with intraperitoneal injection, intranasal instillation yields about a 10-fold increase in sensitivity with an approximate 30-fold reduction in luciferin usage.